Alecensa, also known as alectinib, is a medication used in the treatment of a specific type of lung cancer known as non-small cell lung cancer (NSCLC). This drug is classified as a tyrosine kinase inhibitor, which works by targeting and blocking the activity of certain proteins that are involved in the growth and spread of cancer cells.

Alecensa is typically prescribed for patients with NSCLC that has a specific genetic mutation known as ALK-positive. This mutation causes the cancer cells to grow and spread more rapidly, and Alecensa is specifically designed to target these cells and inhibit their growth.

Clinical studies have shown that Alecensa can be highly effective in treating ALK-positive NSCLC, with many patients experiencing significant tumor shrinkage and prolonged periods of disease control. In some cases, Alecensa has even been shown to be more effective than other standard treatments for this type of cancer.

As with any medication, Alecensa does come with potential side effects. These can include fatigue, nausea, muscle pain, and changes in liver function. It is important for patients to discuss these potential side effects with their healthcare provider and to report any unusual symptoms while taking Alecensa.

Overall, Alecensa has been a valuable addition to the treatment options available for patients with ALK-positive NSCLC. It is important for patients to work closely with their healthcare team to determine if Alecensa is the right treatment option for them and to monitor their progress while taking this medication.